Zhang Hao, Wei Ying-jie, Hu Sheng-shou
Research Center for Cardiac Regenerative Medicine, Ministry of Health, and Department of Cardiac Surgery, Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Semin Thorac Cardiovasc Surg. 2008 Summer;20(2):126-30. doi: 10.1053/j.semtcvs.2008.03.002.
Despite significant improvement in the management of congestive heart failure (CHF), it still is a major worldwide public health problem. Currently, cell-based regenerative medicine has been developed as a promising therapeutic option for patients with CHF. Considering the large and growing population, it is estimated that over 5 million patients in China may need such a cell-based therapy to replace or repair the damaged myocardium. Cardiac surgery has emerged as an important player in heart cell therapy in China in recent years. Here, we summarize our achievements in both preclinical and clinical studies of intraoperative cell transplantation, and present our understanding of future research in this attractive field.
尽管充血性心力衰竭（CHF）的管理有了显著改善，但它仍然是一个全球性的重大公共卫生问题。目前，基于细胞的再生医学已被开发为CHF患者一种有前景的治疗选择。考虑到庞大且不断增长的人口，据估计中国有超过500万患者可能需要这种基于细胞的疗法来替代或修复受损心肌。近年来，心脏手术在中国心脏细胞治疗中已成为一个重要角色。在此，我们总结了术中细胞移植的临床前和临床研究成果，并阐述了我们对这个有吸引力领域未来研究的理解。
